1. Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

2. Introduction Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

3. Study design Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

4. Endpoints Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

5. 5 point scale (Deauville criteria) Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

6. Inclusion and exclusion criteria Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

7. Patient baseline characteristics Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

8. Patient baseline characteristics Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

9. Patient disposition Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

10. Overview of adverse events grade 2 - 4 Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

11. Adverse events grade 3 - 4 patients 18-65 years cycles 1- 4 Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

12. Adverse events grade 3 - 4 patients 66-80 years cycles 1- 4 Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

13. Metabolic complete remission end of induction Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

14. Progression free survival Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

15. Overall survival Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

16. Conclusions Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

17. Acknowledgements Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting